本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

诺瓦瓦克斯医药

6.84
-0.1299-1.86%
成交量:273.62万
成交额:1,888.83万
市值:11.12亿
市盈率:3.30
高:6.98
开:6.91
低:6.82
收:6.97
52周最高:11.55
52周最低:5.01
股本:1.62亿
流通股本:1.37亿
量比:0.98
换手率:2.00%
股息:- -
股息率:- -
每股收益(TTM):2.07
每股收益(LYR):-1.2320
净资产收益率:-898.20%
总资产收益率:18.01%
市净率:-7.09
市盈率(LYR):-5.55

数据加载中...

2024/09/18

关联方拟减持公告

Form 144 | NOVAVAX高管Filip Dubovsky拟减持7335股,总价约95331美元
2024/08/09

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/08/08

重要事件披露

Form 8-K - Current report
2024/08/08

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/06/20

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/06/18

关联方拟减持公告

Form144|诺瓦瓦克斯公司董事James F.Young拟减持15000股,总价约20.57万美元
2024/06/17

关联方拟减持公告

Form144|诺瓦瓦克斯高管Filip Dubovsky拟减持13904股,总价约20万美元
2024/06/14

重要事件披露

Form 8-K - Current report
2024/06/06

重要事件披露

Form 8-K - Current report
2024/05/23

重要事件披露

Form 8-K - Current report
2024/05/20

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/05/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/05/13

重要事件披露

Form 8-K - Current report
2024/05/10

重要事件披露

Form 8-K - Current report
2024/05/10

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/07

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/04/26

重要事件披露

Form 8-K - Current report
2024/04/15

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/04/15

超过5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2024/03/26

重要事件披露

Form 8-K - Current report